Key result
Redo sympathetic renal denervation suggests long-term benefit in highly selected patients with resistant hypertension.
Why the study?
Invasive methods are not guideline-recommended for routine treatment of resistant hypertension, but highly selected patients unresponsive to aggressive medical therapy might benefit.
Case Report (n=1)
Redo sympathetic renal denervation may provide long-term benefits in highly selected patients with resistant hypertension who do not respond to aggressive medical treatment.
Answers are grounded in this paper and cite their sources.
RDN may benefit selected resistant hypertension cases; leaves open routine use pending higher-level evidence.
Sympathetic renal denervation (RDN) has been demonstrated as a potential treatment option for patients with resistant hypertension [1]. Despite discouraging results after the SYMPLICITY HTN-3 trial several techniques and catheters were introduced to the market and data confirming adequate and effective denervation are growing [1, 2]. In current guidelines invasive methods are not recommended as routine treatment of resistant hypertension [3, 4]. However, a highly selected group of patients not responding to aggressive medical treatment might benefit from this method [1–4].
No takes yet. Share an insight, caveat, or question.
Tokarek et al. (2021) conducted a case report in resistant hypertension (n=1). redo sympathetic renal denervation was evaluated. Redo sympathetic renal denervation may provide long-term benefit in highly selected patients with resistant hypertension not responding to aggressive medical treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: